Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
Comparison Between the Efficacy of Rivaroxaban vs Enoxaparin in Post-Operative Deep Venous Thrombosis Prophylaxis After Exploratory Laparotomy
Mayo Hospital Lahore
212 participants
Oct 10, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin. The main questions it aims to answer are: Does rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin? What medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin? Researchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery. Participants will: Take rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery Undergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery Be monitored for bleeding, complications, and other side effects
Eligibility
Inclusion Criteria3
- Both male or female patients
- Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic
- Patients with expected immobility for more than 24 hours
Exclusion Criteria5
- Patients with diagnosed pre-operative DVT
- BMI more than 40
- Patient who are on mechanical ventilation post operatively
- Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident
- Patients who have undergone limb surgery in addition to exploratory laparotomy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Name: Drug: Rivaroxaban Type: Drug Description: Participants receive rivaroxaban 10 mg orally once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.
Name: Drug: Enoxaparin Type: Drug Description: Participants receive enoxaparin 40 mg subcutaneously once daily for 7 days following emergency exploratory laparotomy. All patients also receive standard perioperative management and mechanical prophylaxis as per institutional guidelines.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07243080